Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.44% | 14.55% | 14.15% | 11.55% | 10.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.44% | 14.55% | 14.15% | 11.55% | 10.60% |
| Cost of Revenue | 14.32% | 20.16% | 23.23% | 19.39% | 19.24% |
| Gross Profit | 13.20% | 13.05% | 11.80% | 9.52% | 8.40% |
| SG&A Expenses | 13.78% | 16.95% | 17.20% | 16.49% | 15.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 30.16% | -27.76% | -221.13% | -22,300.00% | 50.78% |
| Total Operating Expenses | 11.43% | 14.28% | 14.32% | 11.90% | 16.52% |
| Operating Income | 18.75% | 15.25% | 13.70% | 10.62% | -2.46% |
| Income Before Tax | -8.92% | -12.87% | -19.42% | -17.78% | 3.11% |
| Income Tax Expenses | 88.59% | 99.18% | 27.71% | 42.60% | 67.12% |
| Earnings from Continuing Operations | -26.11% | -30.43% | -25.20% | -24.36% | -3.42% |
| Earnings from Discontinued Operations | 5.06% | -99.09% | -99.25% | -99.52% | -99.07% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 22.22% | -78.33% | -55.36% | -16.33% | 42.11% |
| Net Income | -25.34% | -75.77% | -73.78% | -74.28% | -67.11% |
| EBIT | 18.75% | 15.25% | 13.70% | 10.62% | -2.46% |
| EBITDA | 17.92% | 14.70% | 12.90% | 9.69% | -1.86% |
| EPS Basic | -24.11% | -75.16% | -73.20% | -73.78% | -66.47% |
| Normalized Basic EPS | 27.92% | 62.77% | 65.78% | 58.93% | 32.44% |
| EPS Diluted | -24.16% | -75.21% | -73.34% | -73.95% | -66.58% |
| Normalized Diluted EPS | 27.81% | 62.64% | 65.79% | 59.13% | 32.71% |
| Average Basic Shares Outstanding | -1.54% | -1.70% | -1.88% | -2.16% | -2.40% |
| Average Diluted Shares Outstanding | -1.45% | -1.63% | -1.87% | -2.24% | -2.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |